实施例4-22中,按照实施例3所示方式,使用不同的的磺酰氯和溶剂。
上述实施例所使用的磺酰氯和产物及分离收率如下表所示:
上述实施例所得到的产品都通过表征数据得到了印证,部分如下:
(4a)白色固体,mp:138-140℃;1HNMR(400MHz,CDCl3)δ6.85(s,1H,NH),5.61(s,1H,NH),3.74(d,J=5.1Hz,2H,-CH2CH2-),3.41(d,J=5.1Hz,2H,-CH2CH2-),2.95(s,3H,-CH3),1.50(d,J=5.5Hz,1H,Cpr-CH),1.37(s,3H,-CH3),1.27(s,3H,-CH3),1.21(d,J=5.5Hz,1H,Cpr-CH).13CNMR(101MHz,CDCl3)δ:173.79,158.16,48.60,41.65,40.66,38.73,27.79,27.33,22.26,18.32.ESI-MS:276([M+H]+).
(4b)白色固体,mp:127-129℃;1HNMR(400MHz,CDCl3)δ6.72(s,1H,NH),5.38(s,1H,NH),3.80–3.64(m,2H,,-CH2CH2-),3.39(m,2H,-CH2CH2-),3.04–2.93(m,2H,-CH2CH2CH2CH3),1.82–1.70(m,2H,-CH2CH2CH2CH3),1.50(d,J=5.7Hz,1H,Cpr-CH),1.44(dd,J=14.9,7.5Hz,2H,-CH2CH2CH2CH3),1.37(s,3H,-CH3),1.27(s,3H,-CH3),1.20(d,J=5.7Hz,1H,Cpr-CH),0.94(t,J=7.3Hz,3H,-CH2CH2CH2CH3).13CNMR(101MHz,CDCl3)δ:173.72,158.14,38.89,27.77,27.28,25.57,22.26,21.52,18.32,13.60.ESI-MS:318([M+H]+).
(4c)白色固体,mp:141-143℃;1HNMR(400MHz,CDCl3)δ6.89(s,1H,NH),5.27(t,J=5.7Hz,1H,NH),3.78–3.65(m,2H,-CH2CH2-),3.33(dd,J=11.1,5.7Hz,2H,-CH2CH2-),2.78(s,6H,-CH3),1.50(d,J=5.7Hz,1H,Cpr-CH),1.37(s,3H,-CH3),1.28(s,3H,-CH3),1.20(d,J=5.7Hz,1H,Cpr-CH).13CNMR(101MHz,CDCl3)δ:173.76,158.25,48.60,42.35,38.50,38.01,27.77,27.29,22.26,18.31.ESI-MS:305([M+H]+).
(4d)白色固体,mp:160-162℃;1HNMR(400MHz,CDCl3)δ7.58(m,2H,C4,5-ArH),7.08(dd,J=4.8,3.9Hz,1H,C3-ArH),6.79(s,1H,NH),5.87(t,J=5.3Hz,1H,NH),3.82–3.60(m,2H,-CH2CH2-),3.31(dd,J=10.7,5.4Hz,2H,-CH2CH2-),1.49(d,J=5.7Hz,1H,Cpr-CH),1.36(s,3H,-CH3),1.29(s,3H,-CH3),1.20(d,J=5.7Hz,1H,Cpr-CH).13CNMR(101MHz,CDCl3)δ:173.62,158.19,140.93,132.14,131.82,127.44,48.63,42.37,38.11,27.92,27.39,22.30,18.30.ESI-MS:344([M+H]+).
(4e)白色固体,mp:162-163℃;1HNMR(400MHz,CDCl3)δ7.72(d,J=8.2Hz,2H,C2,6-ArH),7.29(d,J=8.1Hz,2H,2H,C3,5-ArH),6.83(s,1H,NH),5.72(t,J=5.6Hz,1H,NH),3.79–3.58(m,2H,-CH2CH2-),3.20(q,2H,-CH2CH2-),2.41(s,3H,-CH3),1.46(d,J=5.7Hz,1H,Cpr-CH),1.35(s,3H,-CH3),1.27(s,3H,-CH3),1.18(d,J=5.7Hz,1H,Cpr-CH).13CNMR(101MHz,CDCl3)δ:173.64,158.21,143.35,136.97,129.74,127.05,48.58,41.99,38.28,27.82,27.31,22.27,21.53,18.28.ESI-MS:352([M+H]+).
(4f)白色固体,mp:130-132℃;1HNMR(400MHz,CDCl3)δ7.86(d,J=8.8,5.1Hz,2H,C2,6-ArH),7.17(t,J=8.6Hz,2HC3,5-ArH),6.83(s,1H,NH),5.91(s,1H,NH),3.73–3.59(m,2H,-CH2CH2-),3.23(m,2H,-CH2CH2-),1.47(d,J=5.7Hz,1H,Cpr-CH),1.36(s,3H,-CH3),1.27(s,3H,-CH3),1.19(d,J=5.7Hz,1H,Cpr-CH).13CNMR(101MHz,CDCl3)δ:173.53,158.20,129.77,129.68,116.46,116.24,48.59,41.90,38.24,27.88,27.37,22.25,18.27.ESI-MS:356([M+H]+).
(4g)白色固体,mp:197-199℃,1HNMR(400MHz,CD3OD)δ7.67(d,J=8.7Hz,2H,C3,5-ArH),7.32(d,J=8.7Hz,2H,C2,6-ArH),2.85(t,J=5.3Hz,2H,-CH2CH2-),2.44(t,J=5.3Hz,2H,-CH2CH2-),0.62(d,J=5.2Hz,1H,Cpr-CH),0.61(s,3H,-CH3),0.51(s,3H,-CH3),0.41(d,J=5.2Hz,1H,Cpr-CH).13CNMR(101MHz,CD3OD)δ:175.44,159.07,129.34,125.49,41.65,39.47,28.06,27.49,22.16,18.80.ESI-MS:383([M+H]+).
(4h)白色固体,mp:151-153℃;1HNMR(400MHz,CD3OD)δ8.05(s,1H,C2-ArH),7.70(d,J=8.1Hz,1H,C4-ArH),7.43(d,J=7.7Hz,1H,C6-ArH),7.06(t,J=8.0Hz,1H,C5-ArH),2.86–2.72(m,2H,-CH2CH2-),2.39(t,J=5.8Hz,2H,-CH2CH2-),0.58(d,J=5.5Hz,1H,Cpr-CH),0.57(s,3H,-CH3),0.47(s,3H,-CH3),0.38(d,J=5.5Hz,1H,Cpr-CH).13CNMR(101MHz,CD3OD)δ:175.47,159.07,149.81,144.24,133.60,132.05,128.04,122.89,41.60,39.48,28.08,27.53,22.19,18.82.ESI-MS:383([M+H]+).
(4i)白色固体,mp:180-182℃;1HNMR(400MHz,CDCl3)δ7.15(s,2H,C3,5-ArH),6.95(s,1H,NH),5.53(t,J=5.5Hz,1H,NH),4.13(dt,J=13.5,6.7Hz,2H,-CH(CH3)2),3.73(dd,J=11.0,5.7Hz,2H,-CH2CH2-),3.27–3.14(m,2H,-CH2CH2-),2.97–2.74(m,1H,-CH(CH3)2),1.49(d,J=5.7Hz,1H,Cpr-CH),1.36(s,3H,-CH3),1.27(s,3H,-CH3),1.25(d,J=6.7Hz,18H,-CH(CH3)2),1.20(d,J=5.7Hz,1H,Cpr-CH).13CNMR(101MHz,CDCl3)δ:173.73,158.39,152.54,150.42,132.38,123.66,48.65,41.93,38.34,34.14,29.57,27.88,27.37,24.92,23.59,22.30,18.29.ESI-MS:464([M+H]+).
体内药理学
用两种经典的抗惊厥小鼠试验模型,即最大电休克惊厥发作试验(MES)和戊四唑诱发惊厥发作实验(scPTZtest)测试本发明化合物在小鼠口服后的体内抗惊厥活性。
最大电休克惊厥发作试验(MES):通过用YSD-4G型药理生理实验多用仪装置施加电流(电流为25mA,电压100V,刺激时间0.25s.单次刺激),在体重为18-22g的雄性昆明小鼠中诱发最大电休克癫痫发作。小鼠随机分组,每组10只,口服给本发明化合物不同剂量(300mg/kg,100mg/kg,30mg/kg),1h后,在小鼠两个耳朵上轻轻地固定涂有生理盐水的耳膜电极,然后放开小鼠使其自由运动。施加电流并对动物观察长达30秒的时间,以观察后肢强直性伸展反应的发生。将后肢伸展超过身体平面90度定义为强直性癫痫发作。以量的方式处理结果。
戊四氮诱发惊厥发作试验(scPTZ):小鼠随机分组,每组10只,口服给本发明化合物不同剂量(80mg/kg,40mg/kg,20mg/kg),1h后,皮下注射致惊剂戊四唑(70mg/kg),观察30min,以能否防止小鼠阵发性抽搐维持至少5s以上或者是后肢强直性惊厥为实验最终观察指标。
按照以上方法测定本发明化合物4阻断最大电休克惊厥发作(MES)能力,本发明化合物4均显示对MES的保护作用(见下表)。其中化合物4e和4f抗惊厥作用最强。在给药剂量为30mg/kg时抗惊厥作用与苯妥英钠相当。